A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects with Primary Autonomic Failure
Latest Information Update: 01 Feb 2024
At a glance
- Drugs Ampreloxetine (Primary)
- Indications Orthostatic hypotension
- Focus Adverse reactions
- Acronyms OAK
- Sponsors Theravance Biopharma
Most Recent Events
- 31 Jan 2024 This trial has been discontinued in Portugal, according to European Clinical Trials Database record.
- 01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 22 Mar 2022 This trial has been completed in Poland (End Date: 12 Nov 2021), according to European Clinical Trials Database record.